331 related articles for article (PubMed ID: 30940296)
21. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.
Tan CH; Al-Kalifah N; Ser KH; Lee YC; Chen JC; Lee WJ
Surg Obes Relat Dis; 2018 Oct; 14(10):1600-1606. PubMed ID: 30077664
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
24. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
25. Review article: new treatments in non-alcoholic fatty liver disease.
Townsend SA; Newsome PN
Aliment Pharmacol Ther; 2017 Sep; 46(5):494-507. PubMed ID: 28677333
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.
Francque S; Vonghia L
Adv Ther; 2019 May; 36(5):1052-1074. PubMed ID: 30888594
[TBL] [Abstract][Full Text] [Related]
27. Treatment of NASH with Gastric Bypass.
Jirapinyo P; Thompson CC
Curr Gastroenterol Rep; 2018 Sep; 20(10):49. PubMed ID: 30244334
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Tang JT; Mao YM
J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
[TBL] [Abstract][Full Text] [Related]
29. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
30. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis.
Chen M; Xie Y; Gong S; Wang Y; Yu H; Zhou T; Huang F; Guo X; Zhang H; Huang R; Han Z; Xing Y; Liu Q; Tong G; Zhou H
Pharmacol Res; 2021 Oct; 172():105849. PubMed ID: 34450307
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Gawrieh S; Chalasani N
Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
[TBL] [Abstract][Full Text] [Related]
32. NASH: A glance at the landscape of pharmacological treatment.
Brodosi L; Marchignoli F; Petroni ML; Marchesini G
Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
[TBL] [Abstract][Full Text] [Related]
33. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Hung CK; Bodenheimer HC
Clin Liver Dis; 2018 Feb; 22(1):175-187. PubMed ID: 29128055
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of non-alcoholic fatty liver disease].
Heebøll S; Vilstrup H; Grønbæk H
Ugeskr Laeger; 2018 Jul; 180(31):. PubMed ID: 30064623
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
Wattacheril J; Issa D; Sanyal A
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
[TBL] [Abstract][Full Text] [Related]
36. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
[TBL] [Abstract][Full Text] [Related]
37. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Eshraghian A
World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
[TBL] [Abstract][Full Text] [Related]
38. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement.
Nobili V; Vajro P; Dezsofi A; Fischler B; Hadzic N; Jahnel J; Lamireau T; McKiernan P; McLin V; Socha P; Tizzard S; Baumann U
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):550-61. PubMed ID: 25591123
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
Shen B; Lu LG
J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
[TBL] [Abstract][Full Text] [Related]
40. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Younossi ZM; Reyes MJ; Mishra A; Mehta R; Henry L
Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
